Lin MH, et al. Real-world brigatinib use in non-small cell lung cancer patients with prior use of crizotinib/other ALK therapies in the US. Abstract P2.16-09. WCLC 2019, 7-10 sept. Barcelona, Spanje.
Update KEYNOTE-716: aanhoudend voordeel pembrolizumab bij melanoom
mrt 2024 | Dermato-oncologie